Una Ryan - Albany Molecular Insider

Albany Molecular Research Inc -- USA Stock  

USD 21.74  0.00  0.00%

Lead Independent Director

Dr. Una S. Ryan Ph.D., OBE, is the Lead Independent Director of Albany Molecular Research Inc., since October 2006. She is currently President of Diagnostics for All, a nonprofit focused on lowcost and easytouse diagnostics for the developing world. Previously, she was President and CEO of Waltham Technologies, Inc. a company in the Clean WaterClean Energy business. Concurrently, she holds the position of research professor of medicine at Boston University School of Medicine. Prior to joining Waltham, she was President and CEO of AVANT Immunotherapeutics, Inc. and also a member of its Board of Directors, 1993 to 2007. Prior to AVANT, she was director of Health Sciences at Monsanto Company, 1990 to 1993. Before that, she held a number of positions in academia, including research professor of surgery at Washington University School of Medicine in St. Louis, 1990 to 1994 and professor of medicine at the University of Miami School of Medicine, 1972 to 1989. Dr. Ryan graduated from Englands Bristol University, with B.Sc. degrees in Zoology, Chemistry, and Microbiology. In 2009 she received an Honorary D.Sc. from Bristol University. She received a Ph.D. from Cambridge University. Dr. Ryan has served on several private company boards and industry trade organizations, including the board of BIO, and is past chair of the Massachusetts Biotechnology Council. In 2002, she was awarded the Order of the British Empire for her work to foster and promote biotechnology.
Age: 72  Director Since 2010      
518 512-2000  www.amriglobal.com

Management Efficiency

The company has return on total asset (ROA) of 0.36 % which means that it generated profit of $0.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (20.61) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 647.96 M in liabilities with Debt to Equity (D/E) ratio of 204.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Albany Molecular Research Inc has Current Ratio of 0.67 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Entity Summary

Albany Molecular Research, Inc., a contract research and manufacturing company, offer integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Albany Molecular Research Inc (AMRI) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 2,220 people. Albany Molecular is listed under Business Services category by Fama And French industry classification.

Did you try this?

Run Portfolio Suggestion Now
   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
Hide  View All  Next  Launch Portfolio Suggestion
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Albany Molecular Research Inc to your portfolio

Top Management

Albany Molecular Res Leadership Team
George Svokos, COO, MBA
Arthur Roth, Director
Gerardo Gutierrez, Director
Thomas Ambra, Chairman, Ph.D
Lori Henderson, President
Milton Boyer, President
Anthony Maddaluna, Director, MBA
Kenneth Hagen, Director, CPA
Fernando Napolitano, Director
Una Ryan, Director
David Deming, Director
Kevin Connor, Director
Jimmy Wang, Executive, Ph.D
Gabriel Leung, Director
Steven Hagen, SVP
Christopher Conway, President
Felicia Ladin, President
Veronica Jordan, Director, Ph.D
William Marth, CEO, MBA

Stock Performance

Albany Molecular Performance Indicators